Featured
-
-
Review Article
| Open Access
Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy
- Freya R. Weth
- , Georgia B. Hoggarth
- & Clint Gray
-
Article
| Open Access
Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial
- Jung Hyun Jo
- , Yong-Tae Kim
- & Si Young Song
-
Article
| Open Access
Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms
- Siren Morken
- , Seppo W. Langer
- & Halfdan Sorbye
-
Article
| Open Access
A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer
- Daphne Day
- , John J. Park
- & Archie N. Tse
-
Perspective
| Open AccessEvaluating multi-cancer early detection tests: an argument for the outcome of recurrence-updated stage
- Matthew E. J. Callister
- , Emma J. Crosbie
- & Hilary A. Robbins
-
Article
| Open Access
Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata
- Penella J. Woll
- , Piers Gaunt
- & Lucinda Billingham
-
Article |
Effect of a 1-year physical activity intervention on cardiovascular health in long-term childhood cancer survivors—a randomised controlled trial (SURfit)
- Corina S. Rueegg
- , Simeon J. Zürcher
- & Susi Kriemler
-
Article
| Open Access
A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma
- Juanita Lopez
- , Julia Lai-Kwon
- & Pablo V. Escribá
-
Article
| Open Access
A tailored phase I-specific patient-reported outcome (PRO) survey to capture the patient experience of symptomatic adverse events
- Helena J. Janse van Rensburg
- , Zhihui Liu
- & Aaron R. Hansen
-
Perspective
| Open Access
The National COVID Cancer Antibody Survey: a hyper-accelerated study proof of principle for cancer research
- Matthew Fittall
- , Justin Liu
- & Lennard Y. W. Lee
-
Perspective
| Open AccessRevitalising cancer trials post-pandemic: time for reform
- Cienne Morton
- , Richard Sullivan
- & James Spicer
-
Perspective
| Open AccessIs it still worth pursuing the repurposing of metformin as a cancer therapeutic?
- Simon R. Lord
- & Adrian L. Harris
-
-
Article
| Open Access
Confirmatory prediction-driven RCTs in comparative effectiveness settings for cancer treatment
- Adam Brand
- , Michael C. Sachs
- & Erin E. Gabriel
-
Review Article |
Use of Sequential Multiple Assignment Randomized Trials (SMARTs) in oncology: systematic review of published studies
- Giulia Lorenzoni
- , Elisabetta Petracci
- & Oriana Nanni
-
Comment
| Open AccessAdditional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective
- Sarah P. Blagden
- , Ly-Mee Yu
- & Louise C. Brown
-
Article
| Open Access
Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial
- Shukui Qin
- , Jin Li
- & Jun Zhu
-
Article
| Open Access
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C
- Amelie de Gregorio
- , Wolfgang Janni
- & Nadia Harbeck
-
Article
| Open Access
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
- Dana M. Roque
- , Eric R. Siegel
- & Alessandro D. Santin
-
Article
| Open Access
Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer
- Michelle Harvie
- , Mary Pegington
- & Anthony Howell
-
Article
| Open Access
Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials
- Helen Mossop
- , Michael J. Grayling
- & James M. S. Wason
-
Article
| Open Access
Randomised controlled trial and economic evaluation of a targeted cancer awareness intervention for adults living in deprived areas of the UK
- Yvonne Moriarty
- , Mandy Lau
- & Angela Farr
-
Article
| Open Access
Preventive effect of sensorimotor exercise and resistance training on chemotherapy-induced peripheral neuropathy: a randomised-controlled trial
- Jana Müller
- , Markus Weiler
- & Joachim Wiskemann
-
Article
| Open Access
Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial
- Ivana Sestak
- , Glen Blake
- & Richard Eastell
-
Article
| Open Access
A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours
- Mark T. J. van Bussel
- , Ahmad Awada
- & Jan H. M. Schellens
-
Article
| Open Access
Chemoradiotherapy with extended nodal irradiation and/or erlotinib in locally advanced oesophageal squamous cell cancer: long-term update of a randomised phase 3 trial
- Congying Xie
- , Zhao Jing
- & Shixiu Wu
-
Comment
| Open AccessIncreasing operational and scientific efficiency in clinical trials
- Deirdre Kelly
- , Anna Spreafico
- & Lillian L. Siu
-
Editorial |
Endpoint surrogacy in oncology Phase 3 randomised controlled trials
- Jianrong Zhang
- , Meagan R. Pilar
- & Jianxing He
-
Article
| Open Access
Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis
- Holm Eggemann
- , Cosima Brucker
- & Atanas Ignatov
-
Article
| Open Access
Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials
- Namrata Vijayvergia
- , Arvind Dasari
- & Jonathan R. Strosberg
-
Article
| Open Access
Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer
- Robin M. J. M. van Geel
- , Emilie M. J. van Brummelen
- & Jan H. M. Schellens
-
Consensus Statement
| Open Access
Effective delivery of Complex Innovative Design (CID) cancer trials—A consensus statement
- Sarah P. Blagden
- , Lucinda Billingham
- & Angeliki Yiangou
-
Article
| Open Access
Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
- Heinz Ludwig
- , Wolfram Poenisch
- & Niklas Zojer
-
Brief Communication
| Open Access
Survival benefits of dose-dense early postoperative intraperitoneal chemotherapy in front-line therapy for advanced ovarian cancer: a randomised controlled study
- Tingyan Shi
- , Rong Jiang
- & Rongyu Zang
-
Review Article
| Open Access
The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
- Liese Barbier
- , Paul Declerck
- & Isabelle Huys
-
Article
| Open Access
Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
- Eric Assenat
- , Georges-Philippe Pageaux
- & Valérie Boige
-
Article
| Open Access
Phase III randomised trial comparing 6 vs. 12-month of capecitabine as adjuvant chemotherapy for patients with stage III colon cancer: final results of the JFMC37-0801 study
- Naohiro Tomita
- , Katsuyuki Kunieda
- & Yoshihiko Maehara
-
Article
| Open Access
PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study
- Mark D. Pegram
- , Igor Bondarenko
- & Elizabeth Tan-Chiu
-
Article
| Open Access
A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
- Vera Gorbunova
- , J. Thaddeus Beck
- & Jordan D. Berlin
-
Article
| Open Access
Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint
- Eliana Rulli
- , Francesca Ghilotti
- & Valter Torri
-
Correspondence |
Comment on 'Addition of ultrasound to mammography in the case of dense breast tissue: systematic review and meta-analysis'
- Min Zhu
- , Ming Li
- & Bin Lu
-
Article
| Open Access
Feasibility and acceptability of brief behavioral therapy for cancer-related insomnia: effects on insomnia and circadian rhythm during chemotherapy: a phase II randomised multicentre controlled trial
- Oxana Palesh
- , Caroline Scheiber
- & Karen M. Mustian
-
Article
| Open Access
A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma
- D. H. Palmer
- , Y. T. Ma
- & T. Meyer
-
Epidemiology
| Open Access
Randomised study shows that repeated self-sampling and HPV test has more than two-fold higher detection rate of women with CIN2+ histology than Pap smear cytology
- Inger Gustavsson
- , Riina Aarnio
- & Ulf Gyllensten
-
Clinical Study
| Open AccessS-1 chemotherapy and intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with node-positive gastric cancer: a phase I/II study
- X Wang
- , D B Zhao
- & J Jin
-
Clinical Study
| Open Access
The Improving Rural Cancer Outcomes Trial: a cluster-randomised controlled trial of a complex intervention to reduce time to diagnosis in rural cancer patients in Western Australia
- Jon D Emery
- , Victoria Gray
- & C D'Arcy J Holman
-
Clinical Study
| Open Access
The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
- Usha Menon
- , Alistair J McGuire
- & Ian J Jacobs
-
Translational Therapeutics
| Open Access
Embracing model-based designs for dose-finding trials
- Sharon B Love
- , Sarah Brown
- & Victoria Cornelius
-
Editorial |
Sequential versus concurrent chemotherapy for adjuvant breast cancer: does dose intensity matter?
- N LeVasseur
- & S K Chia
